[Prevention of metastasis with orthomolecular infusions and actovegin].
Hakimi
R
R
D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000191:economics* / Q000628:therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D019317:Evidence-Based Medicine / Q000331:legislation & jurisprudence; D005260:Female; D005858:Germany; D006418:Heme / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D019458:Insurance Coverage / Q000191:economics* / Q000331:legislation & jurisprudence*; D009313:National Health Programs / Q000191:economics* / Q000331:legislation & jurisprudence*; D009974:Orthomolecular Therapy / Q000009:adverse effects / Q000191:economics* / Q000331:legislation & jurisprudence; D055502:Secondary Prevention
D000975:Antioxidants; D006418:Heme; C015646:Actovegin